Sylvia Mechsner

Purpose: Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometrios…

PURPOSE: Relugolix is an oral, non-peptide gonadotropin-releasing hormone receptor antagonist administered as once-daily combination therapy (relugolix-CT; 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) to reduce endometrios…

Supplementary Material 1.

Supplementary Material 1.

Supplementary Material 2.

Supplementary Material 2.

Supplementary Material 3.

Supplementary Material 3.

Supplementary Material 4.

Supplementary Material 4.

Endometriose beeinflusst den Beckenboden funktionell und strukturell: Hypertonus, myofasziale Dysfunktionen und aberrante motorische Muster begünstigen chronische Schmerzen, Blasen- und Darmstörungen sowie Dyspareunie. Therapieansätze umfas…

BACKGROUND: Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis independently …

Abstract Background Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis indepe…

Abstract Background Endometriosis is associated with an increased risk of type I ovarian cancer, yet the prognostic relevance of concurrent endometriosis at diagnosis remains unclear. This cohort study evaluated whether endometriosis indepe…

INTRODUCTION: Endometriosis (EM) is frequently associated with chronic pelvic pain (CPP) and dyspareunia, often linked to secondary pelvic floor dysfunction and hypertonicity. To evaluate whether the use of an intravaginal electromyography …

BACKGROUND: Given the challenges in early detection and diagnosis, understanding the molecular underpinnings of endometrioid ovarian cancer (EOC) is crucial for improving patient outcomes. This multi-level study provides a new perspective o…

Objective The objective of this revised official guideline, published by the German Society for Gynecology and Obstetrics (DGGG) and coordinated in the joint guidelines program of the DGGG, the Austrian Society for Gynecology and Obstetrics…

TARGET GROUP: Physicians interested in endometriosis and infertility as well as medical teams in reproductive medicine and endometriosis centers. OBJECTIVE: A practical guide for clinical decision-making. This guide was compiled by the wor…

Endometriosis is one of the most common causes of chronic pelvic or lower-abdominal pain, yet mechanisms, predictors, and patient-centered treatment pathways remain insufficiently defined. This article summarizes the situation in Germany an…

Endometriosis is a chronic gynecological disorder characterized by persistent pain and impaired quality of life, with limited effective treatment options. Emerging evidence indicates that cannabinoids may provide analgesic and symptom-relie…

INTRODUCTION: A growing body of evidence suggests that women with endometriosis and adenomyosis are at an increased risk of complications during pregnancy and childbirth. Many of these complications are associated with increased blood loss.…

Endometriosis (EM) is a chronic inflammatory disease characterized by the growth of endometrial-like tissue outside the uterus, yet its molecular mechanisms remain poorly understood. This study investigated the expression of mucins (MUC1, M…

Abstract Background The malignant transformation of endometriosis into endometriosis-associated ovarian cancer (EAOC) is still of great interest among researchers. Despite the shared inflammatory and hormonal drivers, the cellular aging dyn…